A density gradient of basement membrane laminins modulates retinal pigment epithelium contractility levels by differential ...

Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03. Anticipation surrounds Lineage ...

Ocular complications in Thalassemia Major are often overlooked, yet early detection through regular eye exams is vital for ...

Cognition Therapeutics (CGTX) reported preclinical data this week at the Association for Research in Vision and Ophthalmology showing the ...

PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Associati ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has dipped by 6.64%, which has investors questioning if this is right time to buy.

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin ...

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related ...

The present study aimed to explore the effects of combination therapy using methotrexate (MTX) and dexamethasone (DEXA) on the expression of genes involved in apoptosis, inflammation and EMT in ...